---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196507"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:09:55.245682+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q2 net loss $26.4M; cash $500.9M; positive EHA data across pipeline

## Summary
- Net loss of $26.4M for Q2 2024 vs $15.9M in Q2 2023; R&D expenses rose to $23.5M.
- Cash, cash equivalents & marketable securities of $500.9M as of June 30, 2024; raised $178M in June offering.
- Presented positive data for bitopertin (EPP), DISC-0974 (anemia of MF), and DISC-3405 (hepcidin) at EHA 2024.
- Expects regulatory interactions for bitopertin and DISC-0974 in H2 2024; DISC-3405 MAD data also expected in H2.
- Cash runway expected to fund operations well into 2027.

## SEC filing metadata
- accession: 0001193125-24-196507
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/0001193125-24-196507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312524196507/d802145d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196507
- JSON: https://secwatch.observer/filing/0001193125-24-196507.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.